The Latest Cardiac and Vascular News
Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended RAASi therapy Veltassa® prevented the recurrence of hyperkalemia events, potentially leading to better patient outcomes Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure […]
Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer) in high risk patient population with heart failure Results suggest that treatment with Veltassa® is beneficial in heart failure patients to control serum potassium levels Veltassa® enabled 85% of patients to be optimized to […]
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy […]
